News Novartis' new drugs outweigh Entresto decline in Q3 Now feeling the impact of generic competition on its top product Entresto in the US, Novartis is still looking for pipeline-building deals, says CEO.
News AbbVie lifted by lengthy delay to generics of Rinvoq Shares in AbbVie were lifted today after the company revealed that it has settled patent litigation with generic drugmakers on blockbuster Rinvoq.
News Zentiva set to change hands in €4.1bn private equity deal Ex-Sanofi generics company Zentiva is poised for a sale by current owner Advent International to US investment group GTCR, says a media report.
News IPO plan evaporates as private equity firm buys Stada Stada has confirmed it isn't going ahead with an IPO, as its two private equity owners have just agreed to sell a majority stake to a third.
News Stada revives talk of an IPO – if conditions improve Germany's Stada has said it may make another attempt to seek a public listing in the autumn, after delaying its plans earlier this year.
News Generic drugmaker Hikma pledges $1bn in US investment With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.